Search research articles
Contact Us
Filters
Showing results (21-30 of 35) with videos related to
Page
of 4
Sort By:
BBA Clinical
|
December 18, 2015
Quantitative proteomics reveals novel therapeutic and diagnostic markers in hypertension
Vittoria Matafora, Laura Zagato, Mara Ferrandi, et al.
International Journal of Molecular Sciences
|
October 19, 2016
Ouabain Contributes to Kidney Damage in a Rat Model of Renal Ischemia-Reperfusion Injury
Luca Villa, Roberta Buono, Mara Ferrandi, et al.
Frontiers in Physiology
|
April 26, 2021
Structural and Electrophysiological Changes in a Model of Cardiotoxicity Induced by Anthracycline Combined With Trastuzumab
Claudia Altomare, Alessandra Maria Lodrini, Giuseppina Milano, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
September 24, 2022
Istaroxime Metabolite PST3093 Selectively Stimulates SERCA2a and Reverses Disease-Induced Changes in Cardiac Function
Martina Arici, Mara Ferrandi, Paolo Barassi, et al.
Journal of Translational Medicine
|
January 19, 2024
Selective SERCA2a activator as a candidate for chronic heart failure therapy
Martina Arici, Shih-Che Hsu, Mara Ferrandi, et al.
Hypertension (Dallas, Tex. : 1979)
|
September 25, 2013
cGMP-dependent protein kinase 1 polymorphisms underlie renal sodium handling impairment
Lorena Citterio, Mara Ferrandi, Simona Delli Carpini, et al.
Journal of Medicinal Chemistry
|
May 17, 2022
Highly Selective SERCA2a Activators: Preclinical Development of a Congeneric Group of First-in-Class Drug Leads against Heart Failure
Andrea Luraghi, Mara Ferrandi, Paolo Barassi, et al.
Science Translational Medicine
|
November 26, 2010
Adducin- and ouabain-related gene variants predict the antihypertensive activity of rostafuroxin, part 2: clinical studies
Chiara Lanzani, Lorena Citterio, Nicola Glorioso, et al.
Vascular Pharmacology
|
July 10, 2024
Istaroxime follow-on compounds: A new class of selective SERCA2a activators for chronic heart failure treatment
Martina Arici, Shih-Che Hsu, Mara Ferrandi, et al.
Cardiovascular Research
|
April 1, 2021
SERCA2a stimulation by istaroxime improves intracellular Ca2+ handling and diastolic dysfunction in a model of diabetic cardiomyopathy
Eleonora Torre, Martina Arici, Alessandra Maria Lodrini, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 35) with videos related to
Sort By:
Page
of 4
BBA Clinical
|
December 18, 2015
Quantitative proteomics reveals novel therapeutic and diagnostic markers in hypertension
Vittoria Matafora, Laura Zagato, Mara Ferrandi, et al.
International Journal of Molecular Sciences
|
October 19, 2016
Ouabain Contributes to Kidney Damage in a Rat Model of Renal Ischemia-Reperfusion Injury
Luca Villa, Roberta Buono, Mara Ferrandi, et al.
Frontiers in Physiology
|
April 26, 2021
Structural and Electrophysiological Changes in a Model of Cardiotoxicity Induced by Anthracycline Combined With Trastuzumab
Claudia Altomare, Alessandra Maria Lodrini, Giuseppina Milano, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
September 24, 2022
Istaroxime Metabolite PST3093 Selectively Stimulates SERCA2a and Reverses Disease-Induced Changes in Cardiac Function
Martina Arici, Mara Ferrandi, Paolo Barassi, et al.
Journal of Translational Medicine
|
January 19, 2024
Selective SERCA2a activator as a candidate for chronic heart failure therapy
Martina Arici, Shih-Che Hsu, Mara Ferrandi, et al.
Hypertension (Dallas, Tex. : 1979)
|
September 25, 2013
cGMP-dependent protein kinase 1 polymorphisms underlie renal sodium handling impairment
Lorena Citterio, Mara Ferrandi, Simona Delli Carpini, et al.
Journal of Medicinal Chemistry
|
May 17, 2022
Highly Selective SERCA2a Activators: Preclinical Development of a Congeneric Group of First-in-Class Drug Leads against Heart Failure
Andrea Luraghi, Mara Ferrandi, Paolo Barassi, et al.
Science Translational Medicine
|
November 26, 2010
Adducin- and ouabain-related gene variants predict the antihypertensive activity of rostafuroxin, part 2: clinical studies
Chiara Lanzani, Lorena Citterio, Nicola Glorioso, et al.
Vascular Pharmacology
|
July 10, 2024
Istaroxime follow-on compounds: A new class of selective SERCA2a activators for chronic heart failure treatment
Martina Arici, Shih-Che Hsu, Mara Ferrandi, et al.
Cardiovascular Research
|
April 1, 2021
SERCA2a stimulation by istaroxime improves intracellular Ca2+ handling and diastolic dysfunction in a model of diabetic cardiomyopathy
Eleonora Torre, Martina Arici, Alessandra Maria Lodrini, et al.
Page
of 4